Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

BGLC

BioNexus Gene Lab Corp

May 17 • 04:00PM ET

0.5739

Dollar change +0.0039
Percentage change 0.68	%

Basic Materials • Specialty Chemicals • Malaysia • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.16	Insider Own	54.93%	Shs Outstand	17.67M	Perf Week	-1.10%
Market Cap	10.14M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	7.96M	Perf Month	-32.37%
Income	-2.66M	PEG	-	EPS next Q	-	Inst Own	0.45%	Short Float	2.22%	Perf Quarter	-44.28%
Sales	9.78M	P/S	1.04	EPS this Y	-	Inst Trans	-	Short Ratio	0.73	Perf Half Y	68.84%
Book/sh	0.53	P/B	1.09	EPS next Y	-	ROA	-27.53%	Short Interest	0.18M	Perf Year	-85.41%
Cash/sh	0.33	P/C	1.74	EPS next 5Y	-	ROE	-33.50%	52W Range	0.31 - 17.88	Perf YTD	8.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-28.24%	52W High	-96.79%	Beta	1.90
Dividend TTM	-	Quick Ratio	3.98	Sales past 5Y	1764.07%	Gross Margin	12.92%	52W Low	85.13%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	4.61	EPS Y/Y TTM	-427.04%	Oper. Margin	-32.83%	RSI (14)	42.85	Volatility	4.83% 7.15%
Employees	18	Debt/Eq	0.01	Sales Y/Y TTM	-4.88%	Profit Margin	-27.25%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-22.92%	Payout	-	Rel Volume	0.16	Prev Close	0.57
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	0.20%	Earnings	-	Avg Volume	240.56K	Price	0.57
SMA20	-3.56%	SMA50	-12.28%	SMA200	-22.26%	Trades		Volume	37,938	Change	0.68%

Apr-19-24 08:58AM	Why Is BioNexus Gene Lab (BGLC) Stock Down 27% Today? (InvestorPlace) -29.32%
Apr-18-24 02:52PM	BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in Healthcare (GlobeNewswire) +34.00%
Jul-24-23 11:30AM	BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital Market (GlobeNewswire) -10.08%
Jul-20-23 01:29PM	BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital Market (GlobeNewswire) -55.40%

BioNexus Gene Lab Corp. operates as a holding company, which engages in the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries. It is also involved in the development of liquid biopsy tests for the early detection of biomarkers that are linked to diseases. It operates through the BioNexus Malaysia and Chemrex segments. The company was founded on May 12, 2017 and is headquartered in Kuala Lumpur, Malaysia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BGLC

BioNexus Gene Lab Corp

Upgrade your FINVIZ experience